Investigating the Effects of Secondary Metabolites of Streptomyces Calvus Bacteria on Human Liver Cancer Cells (HCC)

Haleh Halali; Mahnaz Mohammadi

doi:10.18502/ssu.v33i5.19328

Haleh Halali Department of Biology, Faculty of Basic Sciences, Islamic Azad University, Islamshahr Branch, Islamshahr, Tehran, Iran.
Mahnaz Mohammadi Department of Biology, Faculty of Basic Sciences, Islamic Azad University, Islamshahr Branch, Islamshahr, Tehran, Iran.

DOI: https://doi.org/10.18502/ssu.v33i5.19328

Keywords: hepatocellular carcinoma، Streptomyces callus، secondary metabolites، drug resistance

Abstract

Introduction: The liver is a vital organ that plays a role in various important metabolic functions in the body. This study aimed to investigate the anticancer effects of secondary metabolites from Streptomyces calvus isolate ABRINW 673 on Hep-G2 cancer cell line (human liver cancer).

Methods: To achieve this, Hep-G2 cells were treated with different concentrations of secondary metabolites from Streptomyces calvus for duration ranging from 12 to 72 hours. The Trypan blue dye removal test was utilized to investigate the growth inhibition effects of metabolites، Wright-Giemsa staining was employed to investigate the morphology of cancer cells, and DNA fragmentation test along with Real time PCR were used to explore the apoptotic effects of metabolites.

Results: Secondary metabolites of Streptomyces calvus isolated 673 caused concentration- and time-dependent growth inhibition in Hep-G2leading to decreased viability, inhabitation of growth، induction of apoptosis, and morphological changes in Hep-G2 cells. The expression level of P53 gene increased from 1 to 3 due to treatment with Streptomyces calvus metabolites whereas BCL2 decreased from 1 to nearly zero. Furthermore, the expression level of the Bax gene rose from 1 to 2.5 following treatment with the bacterial secondary metabolite.

Conclusion: Based on the mentioned effects of the secondary metabolites from Streptomyces calvus, they can be suggested as a novel and effective compounds for further studies in the treatment of patients with hepatocellular carcinoma.